Name
norepinephrine
Label
Norepinephrine
Units
ng/mL
Type
numeric
Visit number vs Norepinephrine
N | Mean | StdDev | Median | Min | Max | Unknown | Total | |
---|---|---|---|---|---|---|---|---|
Baseline | 49 | 47.4 | ± 36.0 | 39.7 | 4.3 | 183.0 | - | 49 |
9-Month Followup | 42 | 71.0 | ± 53.7 | 55.5 | 5.9 | 230.0 | 1 | 43 |
18-Month Followup | 39 | 63.9 | ± 60.7 | 47.6 | 4.5 | 279.0 | 1 | 40 |
Randomized treatment arm vs Norepinephrine
Baseline
N | Mean | StdDev | Median | Min | Max | Unknown | Total | |
---|---|---|---|---|---|---|---|---|
Total | 49 | 47.4 | ± 36.0 | 39.7 | 4.3 | 183.0 | - | 49 |
Laparoscopic Gastric Banding (LGB) | 28 | 47.5 | ± 36.9 | 42.0 | 4.3 | 183.0 | - | 28 |
Continuous Positive Airway Pressure (CPAP) | 21 | 47.3 | ± 35.7 | 39.4 | 7.9 | 135.0 | - | 21 |
Randomized treatment arm vs Norepinephrine
9-Month Followup
N | Mean | StdDev | Median | Min | Max | Unknown | Total | |
---|---|---|---|---|---|---|---|---|
Total | 42 | 71.0 | ± 53.7 | 55.5 | 5.9 | 230.0 | 1 | 43 |
Laparoscopic Gastric Banding (LGB) | 24 | 68.1 | ± 50.8 | 55.5 | 5.9 | 219.0 | 1 | 25 |
Continuous Positive Airway Pressure (CPAP) | 18 | 74.9 | ± 58.5 | 54.9 | 24.3 | 230.0 | - | 18 |
Randomized treatment arm vs Norepinephrine
18-Month Followup
N | Mean | StdDev | Median | Min | Max | Unknown | Total | |
---|---|---|---|---|---|---|---|---|
Total | 39 | 63.9 | ± 60.7 | 47.6 | 4.5 | 279.0 | 1 | 40 |
Laparoscopic Gastric Banding (LGB) | 24 | 58.2 | ± 44.3 | 48.8 | 4.5 | 166.0 | - | 24 |
Continuous Positive Airway Pressure (CPAP) | 15 | 73.0 | ± 81.4 | 42.5 | 13.6 | 279.0 | 1 | 16 |
Age of the participant vs Norepinephrine
Baseline
N | Mean | StdDev | Median | Min | Max | Unknown | Total | |
---|---|---|---|---|---|---|---|---|
Total | 49 | 47.4 | ± 36.0 | 39.7 | 4.3 | 183.0 | - | 49 |
27.0 to 45.0 years | 13 | 57.4 | ± 40.0 | 46.3 | 7.9 | 135.0 | - | 13 |
46.0 to 50.0 years | 12 | 48.9 | ± 24.4 | 42.0 | 15.1 | 113.0 | - | 12 |
51.0 to 56.0 years | 12 | 53.1 | ± 48.6 | 38.5 | 12.4 | 183.0 | - | 12 |
57.0 to 65.0 years | 12 | 29.4 | ± 21.1 | 20.3 | 4.3 | 71.8 | - | 12 |
Age of the participant vs Norepinephrine
9-Month Followup
N | Mean | StdDev | Median | Min | Max | Unknown | Total | |
---|---|---|---|---|---|---|---|---|
Total | 42 | 71.0 | ± 53.7 | 55.5 | 5.9 | 230.0 | 1 | 43 |
28.0 to 47.0 years | 11 | 65.8 | ± 49.8 | 47.5 | 24.3 | 193.0 | - | 11 |
47.0 to 52.0 years | 11 | 69.2 | ± 38.3 | 57.0 | 10.0 | 140.0 | - | 11 |
52.0 to 58.0 years | 11 | 78.4 | ± 75.8 | 61.8 | 5.9 | 230.0 | - | 11 |
58.0 to 65.0 years | 9 | 70.8 | ± 50.4 | 64.4 | 16.6 | 173.0 | 1 | 10 |
Age of the participant vs Norepinephrine
18-Month Followup
N | Mean | StdDev | Median | Min | Max | Unknown | Total | |
---|---|---|---|---|---|---|---|---|
Total | 39 | 63.9 | ± 60.7 | 47.6 | 4.5 | 279.0 | 1 | 40 |
29.0 to 46.0 years | 10 | 94.1 | ± 87.1 | 65.7 | 13.6 | 279.0 | - | 10 |
47.0 to 52.0 years | 9 | 60.5 | ± 38.7 | 50.0 | 6.6 | 130.0 | 1 | 10 |
53.0 to 58.0 years | 10 | 38.7 | ± 49.9 | 18.3 | 11.6 | 168.0 | - | 10 |
58.0 to 65.0 years | 10 | 62.1 | ± 49.1 | 52.4 | 4.5 | 166.0 | - | 10 |
Gender of the participant vs Norepinephrine
Baseline
N | Mean | StdDev | Median | Min | Max | Unknown | Total | |
---|---|---|---|---|---|---|---|---|
Total | 49 | 47.4 | ± 36.0 | 39.7 | 4.3 | 183.0 | - | 49 |
Male | 28 | 55.1 | ± 38.8 | 43.1 | 14.3 | 183.0 | - | 28 |
Female | 21 | 37.1 | ± 29.6 | 30.7 | 4.3 | 113.0 | - | 21 |
Gender of the participant vs Norepinephrine
9-Month Followup
N | Mean | StdDev | Median | Min | Max | Unknown | Total | |
---|---|---|---|---|---|---|---|---|
Total | 42 | 71.0 | ± 53.7 | 55.5 | 5.9 | 230.0 | 1 | 43 |
Male | 25 | 82.3 | ± 56.9 | 63.0 | 10.0 | 230.0 | - | 25 |
Female | 17 | 54.4 | ± 45.2 | 36.7 | 5.9 | 173.0 | 1 | 18 |
Gender of the participant vs Norepinephrine
18-Month Followup
N | Mean | StdDev | Median | Min | Max | Unknown | Total | |
---|---|---|---|---|---|---|---|---|
Total | 39 | 63.9 | ± 60.7 | 47.6 | 4.5 | 279.0 | 1 | 40 |
Male | 25 | 79.8 | ± 68.0 | 65.7 | 13.6 | 279.0 | - | 25 |
Female | 14 | 35.7 | ± 29.9 | 21.0 | 4.5 | 92.9 | 1 | 15 |
Race of the participant vs Norepinephrine
Baseline
N | Mean | StdDev | Median | Min | Max | Unknown | Total | |
---|---|---|---|---|---|---|---|---|
Total | 46 | 47.7 | ± 36.9 | 39.6 | 4.3 | 183.0 | - | 46 |
white | 35 | 46.6 | ± 39.2 | 39.4 | 7.9 | 183.0 | - | 35 |
american indian or alaska native | - | - | - | - | - | - | - | - |
black or african american | 9 | 47.7 | ± 28.4 | 39.7 | 4.3 | 103.0 | - | 9 |
asian | 2 | 66.1 | ± 40.9 | 66.1 | 37.1 | 95.0 | - | 2 |
native hawaiian or other pacific islander | - | - | - | - | - | - | - | - |
other | - | - | - | - | - | - | - | - |
multiple | - | - | - | - | - | - | - | - |
Race of the participant vs Norepinephrine
9-Month Followup
N | Mean | StdDev | Median | Min | Max | Unknown | Total | |
---|---|---|---|---|---|---|---|---|
Total | 39 | 70.7 | ± 55.7 | 50.6 | 5.9 | 230.0 | 1 | 40 |
white | 30 | 72.8 | ± 61.0 | 49.4 | 5.9 | 230.0 | 1 | 31 |
american indian or alaska native | - | - | - | - | - | - | - | - |
black or african american | 8 | 68.5 | ± 32.7 | 71.0 | 26.7 | 115.0 | - | 8 |
asian | 1 | 24.3 | - | 24.3 | 24.3 | 24.3 | - | 1 |
native hawaiian or other pacific islander | - | - | - | - | - | - | - | - |
other | - | - | - | - | - | - | - | - |
multiple | - | - | - | - | - | - | - | - |
Race of the participant vs Norepinephrine
18-Month Followup
N | Mean | StdDev | Median | Min | Max | Unknown | Total | |
---|---|---|---|---|---|---|---|---|
Total | 36 | 65.4 | ± 62.6 | 45.1 | 4.5 | 279.0 | 1 | 37 |
white | 28 | 66.9 | ± 69.2 | 43.5 | 4.5 | 279.0 | 1 | 29 |
american indian or alaska native | - | - | - | - | - | - | - | - |
black or african american | 7 | 64.0 | ± 33.5 | 50.0 | 19.6 | 102.0 | - | 7 |
asian | 1 | 33.6 | - | 33.6 | 33.6 | 33.6 | - | 1 |
native hawaiian or other pacific islander | - | - | - | - | - | - | - | - |
other | - | - | - | - | - | - | - | - |
multiple | - | - | - | - | - | - | - | - |